Early carbohydrate antigen 125 as a mortality predictor in hospitalized patients with coronavirus disease 2019.

ABSTRACT:

Background

Carbohydrate antigen 125 (CA125) is an indicator of inflammation, immune response, and impaired cardiac function. The aim was to investigate whether CA125 behaves as a biomarker of severity and poor clinical outcomes in hospitalized patients with coronavirus disease 2019 (COVID-19).

Methods

Serum CA125 [Elecsys CA125 II assay-(Roche Diagnostics GmbH)] was measured in stored biobank samples from COVID-19 hospitalized patients between 01 March 2020 and 17 October 2021. Multiple logistic regression models were built to explore the association between CA125 and clinical outcomes [in-hospital all-cause mortality, need for invasive mechanical ventilation (IMV), or non-invasive respiratory support (non-IRS)], estimating odds ratios (ORs; 95% CI). The gradient of risk of

SUBMITTER: Moreno-Perez O 

PROVIDER: S-EPMC9631479 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature